Several monogenic cardiac disorders are associated with sudden cardiac death. These include primary electrophysiological disorders (long QT, short QT, Brugada, and catecholaminergic ventricular tachycardia syndromes) and cardiomyopathies, including hypertrophic and dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.
T he annual incidence of sudden cardiac death (SCD) in the United States exceeds 300,000 cases per year (1) . In athletes, it has an incidence of 1:80,000 to 1:40,000, although it seems to occur more frequently in AfricanAmerican athletes (2) . There are known risk factors such as diabetes mellitus, hyperlipidemia, smoking in patients with coronary artery disease, and left ventricular hypertrophy (LVH). A number of patients with SCD have a predisposition that is genetically determined and which interacts with environmental factors. There are also diseases that are primarily monogenic in inheritance and can lead to SCD. These include myocardial diseases (10% to 15% of cases of SCD), primary electrophysiological (EP) problems (5% of cases), and rare vascular disorders. The present review addresses the implications for imaging with respect to the genotype-phenotype relations in these monogenic disorders (1) .
PRIMARY EP DISEASES
Long QT syndrome (LQTS), Brugada syndrome, short QT syndrome, and catecholaminergic ventricular tachycardia all cause SCD. Although EP abnormalities are readily recognized as important findings in these diseases, abnormalities in cardiac function have more recently been reported in some patients with LQTS.
LQTS is caused by mutations in proteins that encode the sodium and potassium ion channels. Some syndromes have an autosomal dominant inheritance; it is autosomal recessive in others, as in the Jervell and Lange-Nielsen syndrome in which deafness occurs along with SCD. LQTS1 and LQTS2 are due to potassium channel mutations, and LQTS3 is due to sodium channel mutations. In LQTS, action potential duration is prolonged due to delayed repolarization, which is associated with early afterdepolarizations and with electrical dispersion. Predictors of cardiac events in this patient population include LQTS locus, sex, and QTc duration. In particular, QTc duration (>500 ms) is an independent predictor of cardiac events in patients with LQTS1 and LQTS2 but not in those with LQTS3 (3).
The aforementioned electrical abnormalities result in prolongation of contraction duration that may be detected by using myocardial imaging ( Figure 1) . A study in 101 genotyped subjects with LQTS revealed several abnormalities when patients and mutation carriers were compared with control subjects. Not only was the duration of contraction prolonged (determined by the time interval from QRS complex to peak strain), but contraction was prolonged by variable durations in the examined left ventricular (LV) segments (4) . Furthermore, transmural differences were observed such that contraction prolongation was more pronounced in the subendocardial layer than in the mid-myocardial layer, as reflected in longitudinal and circumferential strains, respectively. There were interesting genotype-phenotype correlations seen in this investigation. The transmural differences were most noticeable in patients with double mutations (Jervell and Lange-Nielsen), followed by those having LQTS2 and the least in patients with LQTS1 (4) . In a retrospective analysis, the mechanical dispersion seen in longitudinal strain was a better predictor of events (arrhythmia, syncope, and cardiac arrest) than QTc duration (4) .
Thus, in the case of LQTS, myocardial imaging seems to add to the genotype information, not only to achieve better understanding of the extent of disease but also in risk stratification. Its role needs further evaluation in prospective studies.
HYPERTROPHIC CARDIOMYOPATHY
Hypertrophic cardiomyopathy (HCM) affects w0.2% of the population and is an important, potentially preventable cause of SCD in young athletes, if diagnosed early and appropriate restrictions are applied (5) . Several mutations reportedly cause the disease ( Table 1) . The likelihood of finding 1 of the causative mutations is lower in sporadic cases versus familial cases (30% to 40% vs. 60% to 70%). Previous publications emphasized the presence of malignant mutations (more frequently in MYH7 and TNNT2), which are characterized by younger age at presentation, more severe LVH (but not for TNNT2 mutations), and higher incidence of SCD. Recent reports noted an overall lower incidence of such mutations in nonfamilial cases and inconsistency in their association with a given phenotype and clinical outcome (6, 7) . Furthermore, there is substantial heterogeneity in phenotypic presentation even among patients with the same mutation. Although HCM is an example of a monogenic disorder, it is increasingly recognized that gene-gene interactions, as well as geneenvironment interactions, determine a given subject's phenotype, with more severe disease in patients with multiple mutations (even if they are apparently benign mutations) (8) .
Presently, there is a limited role for genetic testing in a given subject with known disease to guide treatment decisions, although the mere presence of a known mutation is associated with worse overall outcome irrespective of the mutation type (9) . With respect to implications for management, the consensus at the present time is that the general guidelines for HCM patients with LVH should not be applied to patients who carry known mutations but lack hypertrophy. Recommendations with respect to exercise activity and potential treatment to prevent development of LVH and SCD await further observational and randomized clinical studies.
Heterogeneity in segmental function is a hallmark of HCM that occurs even in preclinical disease (13) (14) (15) (16) . Only a few studies have attempted to explain these observations as they relate to molecular and cellular heterogeneity. One report assessed cardiac tissue from an HCM patient with advanced heart failure but with preserved ejection fraction (EF) who underwent cardiac imaging just before heart transplantation. Wide segmental variation in the molecular expression of several Myosin-binding protein C (MYBPC3); 15%-25% 11p11.2 Glu258Lys, Glu451Gln, Arg495Gln, Arg502Gln
Beta-myosin heavy chain 7 (MHC7); 15%-25% 14q11.2 Arg403Gln, Arg453Cys, Gly716Arg, Arg719Trp
Alpha-myosin heavy chain 6 (MHC6); <1% 14q11.2-q12 Gln1065His
Cardiac troponin T (TNNT2); <5% 1q32 Phe70Leu, Arg102Leu, Pro120Val, Arg286Cys
Cardiac troponin I (TNNI3); <5% 19p13.4 Arg141Gln, Ala157Val, Arg162Po, Arg186Gln
Cardiac troponin C (TNNC1); <1% 3p21.1 Leu29Gln, Ala8Val, Cys84Tyr, Cys35Ser
Alpha-tropomyosin (TPM1); <5% 15q22.2 Asp175Asn; Glu180Gly
Alpha-actin (ACTC1); <1% 15q14 Ala295Ser
Alpha-actinin 2 (ACTN2); <1% 1q43 Ala119Thr, Thr495Met, Glu583Ala, and Glu628Gly
Myosin regulatory light chain 2 (MYL2); <2% 12q24.11 Phe18Leu, Arg58Gln
Essential myosin light chain 3 (MYL3); <1% 3p21.31 E56G
Telethonin (TCAP); <1% 17q12 Thr137Ile, Arg153His
Phospholamban (PLN); <1% 6q22.31 77A-G, 42C-G (both in gene promoter region)
Muscle LIM protein (CSRP3); <1% 11p15.1 Leu44Pro, Ser54Arg/Glu55Gly, Cys58Gly
Titin (TTN); <1% 2q24. (DCM), and it affects both male and female subjects.
DILATED CARDIOMYOPATHY
Idiopathic DCM includes diseases caused by genetic defects and is an important cause of heart failure and SCD. The disease had a prevalence of 1:2,500 in 1 study (35) . There is an asymptomatic stage of LV systolic dysfunction characterized by LV remodeling and depressed EF, which is usually followed by a Figure 2 . These syndromes include Emery-Dreifuss muscular dystrophy, limb-girdle muscle dystrophy, Duchenne and Becker muscular dystrophies, and Kearns-Sayre syndrome. In addition to cardiac involvement, patients with these syndromes present with muscle weakness of special muscle groups and elevated creatine kinase levels. Table 2 displays a list of DCMcausing mutations (38, 39) . A recent study noted that mutations in the A-band region of TTN are frequent causes of the disease (they were detected in 27% of patients with DCM) (40) . As shown in Tables 1 and 2 Nagueh and Zoghbi to identify mural thrombi because their presence has direct implications for management and the administration of anticoagulants.
A B N O R M A L L V S T R U C T U R E
Clinically, presentation varies, from asymptomatic family members with the classic morphology to patients with heart failure, embolic events, and SCD. In addition, LV noncompaction can be present as 1 of the manifestations of clinical syndromes in which skeletal myopathy occurs (e.g., Barth syndrome) ( Table 3) .
Implantable cardioverter-defibrillator (ICD) implantation is guided by the presence or absence of sustained ventricular tachycardia, LV remodeling, extent of noncompaction, and LV EF, among other parameters of myocardial function; few data exist overall, however.
SCREENING OF FAMILY MEMBERS.
For patients with LV noncompaction, identification of a known mutation can help inform the recommendation to offer genetic testing to relatives. In the absence of a known mutation, first-degree family members should be screened by using clinical evaluation, ECGs, and echocardiography at 3-year intervals. When the relative is known to carry the mutation, screening in childhood should be considered at yearly intervals and for adults at 1-to 3-year intervals (47) .
ARRHYTHMOGENIC RV CARDIOMYOPATHY
ARVC is an important cause of SCD in younger subjects and athletes and usually has an autosomal The figure shows the findings on 2-dimensional echocardiographic imaging of an LV apical long-axis view from a patient with LV noncompaction. Multiple trabeculations and recesses in the inferolateral wall at (left) end diastole and (right) end systole are displayed.
Abbreviation as in Figure 3 . Table 4 ). In addition, some patients harbor multiple mutations (56), both compound (both alleles of the same gene) and digenic (mutations in 2 different genes). Clinically, RV dysfunction can be an isolated finding or a component of a clinical syndrome.
These include Naxos disease, which is characterized by palmoplantar keratoderma and woolly hair with autosomal recessive inheritance (57), and Transforming growth factor beta-3 (TGFB3) 14q24. CONSIDERATIONS FOR GENETIC TESTING AND ROLE OF IMAGING. As detailed in Table 5 , imaging plays an important role in establishing a diagnosis.
Once the diagnosis is established, genetic testing can be offered to identify first-degree relatives with positive mutations (overall yield of genetic testing is w50%). This strategy is contingent on identifying a known mutation in the proband. Genetic testing is usually not needed to confirm the clinical diagnosis. Tables 1 to 5 . (38) .
CONCLUSIONS
Imaging plays an important role in establishing the diagnosis of many of the monogenic cardiac disorders associated with SCD ( Table 6 ). The correct diagnosis expectedly leads to the timely initiation of treatment and affords families the possibility of genetic counseling once the pathogenic mutation in the proband is determined. In addition, key findings noted according to imaging can identify patients at a high risk for SCD and can be used to inform the decision for ICD implantation. Imaging has also been used to screen family members because abnormalities in cardiac structure and function may be detected at a stage preceding the development of the pathognomonic phenotype (Central Illustration). 
